The IMPALA-2 autoimmune pulmonary alveolar proteinosis (aPAP) trial
Breathing new life into aPAP research
Why we’re doing this research
Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare lung disease with no approved pharmacologic treatment options. The disease is characterized by the build-up of surfactant in the alveoli (air sacs) of the lungs leading to impaired oxygen transfer from the lungs to the blood.
People with aPAP may experience symptoms like shortness of breath and a decreased ability to exercise. Typically, shortness of breath is first observed upon exertion, but as the disease progresses, shortness of breath can be experienced even when a person is at rest. Cough, as well as episodes of fever, can also be experienced especially if secondary lung infection develops. In the long-term, the disease can lead to serious complications, including lung fibrosis and the need for lung transplant.